Xenon Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Xenon Pharmaceuticals Inc. on July 3, 2018. The report details a significant capital raising event involving an at-the-market equity offering program.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. The primary financial metric disclosed relates to the equity offering:
- Program Cap: Up to $30.0 million in aggregate sales proceeds.
- Shares Sold: 3,440,000 common shares.
- Proceeds Raised: Approximately $29.2 million (net of commissions).
Material Changes
The material change reported is the near-completion of the at-the-market equity offering sales agreement entered into on May 8, 2018, with Stifel, Nicolaus & Company, Incorporated. As of the report date, the Company had raised approximately 97% of the authorized $30.0 million target.
Outlook and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the equity offering mechanics. The transaction was executed through Stifel acting as a sales agent.
Investor Verification Checklist
- Verify the exact net proceeds of $29.2 million against the company's cash balance in subsequent filings.
- Confirm the total number of outstanding shares post-issuance to assess dilution impact.
- Review the specific commission rates paid to Stifel to understand the cost of capital.
- Check if the remaining $0.8 million of the program was subsequently utilized or terminated.